Collaborators

SYNERGI24 is a collaboration between Örebro University, clinical and academic partners, and four business partners. The collaboration is designed for co-production, ensuring that research outputs are continuously shaped toward actionable tools, models, and interventions.

QIAGEN AB contributes advanced expertise in multi-omics integration and bioinformatics, enabling the analysis of genomic, transcriptomic, and microbiome data. Using established platforms such as CLC Genomics Workbench and Ingenuity Pathway Analysis, QIAGEN supports the integration of clinical and molecular datasets to identify key pathways linking TMAO to chronic inflammatory diseases. Their role ensures robust data processing, interpretation, and identification of therapeutic targets.


Redoxis AB provides expertise in in vivo disease modelling and redox biology, focusing on oxidative stress and inflammatory mechanisms. Within the project, Redoxis supports the development and validation of experimental models to investigate systemic effects of TMAO and to translate in vitro findings into physiologically relevant systems.


Bio-Rad Laboratories AB contributes state-of-the-art proteomics and multiplex assay platforms for biomarker discovery and validation. Their technologies enable high-throughput profiling of inflammatory and metabolic proteins, ensuring robust validation of TMAO-associated pathways and supporting the translation of findings into clinically relevant biomarkers.


PROBI AB contributes expertise in probiotic development and microbiome modulation. The company supports the identification and evaluation of probiotic strains capable of reducing TMAO levels and modulating inflammation, providing a foundation for novel, non-pharmacological intervention strategies.

Clinical and academic partners:

  • Karolinska University Hospital
  • Karolinska institute
  • Region Örebro Län
  • University of Lincoln (UK)